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Abstract: Inhibition of tumor growth induced by treatment with direct electric current (DC) has 
been reported in several models. One of the mechanisms responsible for the antitumoral activity 
of DC is the generation of oxidative species, known as chloramines. With the aim of increas-
ing chloramine production in the electrolytic medium and optimizing the antitumoral effects 
of DC, poly(ε-caprolactone) (PCL) nanoparticles (NPs) loaded with the amino acid tyrosine 
were obtained. The physical–chemical characterization showed that the NPs presented size in 
nanometric range and monomodal distribution. A slightly negative electrokinetic potential was 
also found in both blank NPs and l-tyrosine-loaded PCL NPs. The yield of the loading process 
was approximately 50%. Within 3 h of dissolution assay, a burst release of about 80% l-tyrosine 
was obtained. The in vitro cytotoxicity of DC was significantly increased when associated with 
l-tyrosine-loaded NPs, using a murine multidrug-resistant melanoma cell line model. This study 
showed that the use of the combination of nanotechnology and DC has a promising antineoplastic 
potential and opens a new perspective in cancer therapy.
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Introduction
Nanoparticulate systems show promise as active vectors because of their capacity to 
release substances.1 The advantages of using this approach for drug delivery result 
from some interesting properties of these systems. Because of their small size, they can 
travel through the endothelium of inflammatory sites, epithelium (eg, intestinal tract and 
liver), and tumors or penetrate microcapillaries.2 In addition to their biodegradability 
and biocompatibility, the use of these delivery systems result in increased bioavailability 
of transported drugs with minimal toxicity.3,4 Nanoparticle (NP) systems have recently 
been incorporated within cancer therapies, because of their ability to concentrate 
drugs at the tumor site, which enhances their cytotoxic effects on the cancer cells and 
therefore reduces systemic side effects.5–7
Poly (ε-caprolactone) (PCL) is an aliphatic polyester that is used to develop inject-
able sustained delivery systems, such as polymeric NPs.8 PCL NPs have been used as 
drug-carrier systems for amphotericin B,9,10 indomethacin,11 griseofulvin,12 tamoxifen,13 
vaccines,14 magnetic composites,15 and cyclosporine A.16 PCL NP production by the 
double emulsion solvent evaporation method (DEEM) has been shown to exhibit 
satisfactory encapsulation efficiency for hydrophilic drugs.17–19
Scientific investigations have demonstrated that electrotherapy (EChT) presents 
an effective approach for treating several types of cancer.20–22 EChT uses a low direct 
electric current (DC) to treat tumor tissue through two or more electrodes placed International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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within the tumoral zone or within its surrounding area. 
This treatment is noted for its significant effectiveness, 
minimal invasiveness, localized action, and low cost.23–25 
Nordenström discussed the mechanisms associated with this 
therapy, such as pH alterations, electroosmotic transport of 
water, and the effects on ionic transmembrane flow, as par-
tially responsible for the efficacy of EChT.26,27
An important milestone for the study of EChT was the 
development of an in vitro experimental model for inves-
tigation of DC effects on culture cell lines.28–30 Using this 
model, Veiga et al showed that DC can destroy tumor cells 
via two distinct mechanisms: apoptosis and necrosis.30 Both 
aforementioned mechanisms appear to be associated with 
the DC polarity: cells exposed to anodic flow (AF) undergo 
mostly apoptosis, whereas those exposed to cathodic flow 
(CF) die almost entirely as a result of necrosis.30 These 
authors attributed the apoptotic cell death to chlorinated 
species (Cl−, Cl2, HOCl) generated by AF, which react with 
amino acids to produce oxidizing and apoptosis-inducing 
molecules called chloramines. As a matter of fact, other 
studies developed using different reactive oxygen species 
have proven that oxidants, hypochlorous acid and chloram-
ines, induced apoptotic cell death from the reaction of 
chlorinated species with free amino acids present in the cell 
suspension.31,32 Englert and Shacter32 compared the influence 
of different amino acids (taurine, arginine, lysine, glutamic 
acid, glutamine, and isoleucine) on the viability of lymphoma 
cells in the presence of oxidant compounds. These authors 
showed that depending on the kind of amino acids, cell death 
by necrosis or apoptosis was detected in the cellular medium. 
In their experimental model, the formation of chloramines 
generated by the reaction of H2O2 with glutamine and arginine 
induced exclusively apoptosis and necrosis, respectively.32 
Indeed, Veiga et al confirmed this hypothesis by adding 
l-glutamine to the electrolytic medium during exposure of 
human leukemic cells to AF generated by DC.30 Besides, 
L-tyrosine, L-glutamine, and L-tryptophan were also tested 
in B16F10 murine melanoma cells, and the highest cytotoxic 
effects induced by chloramines generated by DC stimulation 
were obtained in the presence of L-tyrosine (unpublished 
data). Considering this preliminary screening, L-tyrosine 
was the amino acid chosen for the present study.
Given the results of these previous works, it is likely that 
amino acid encapsulation within NPs may modulate chloram-
ine production within the AF and, most importantly, increase 
its delivery to target cells. Targeted drug delivery would 
enhance the damage induced by these molecules and thus 
improves DC antitumoral activity. To verify this hypothesis, 
the present work describes the use of nanotechnology in 
association with DC for the first time. l-Tyrosine was loaded 
onto PCL polymer, and the physical and chemical parameters 
of this loading process were determined. Additionally, the 
cytotoxicity of this association was evaluated in murine 
multidrug-resistant melanoma cell line B16F10. Our results 
show that the use of nanotechnology along with DC has a 
promising antineoplastic potential.
Material and methods
Chemicals
The following chemicals were purchased from VETEC 
Química Fina (Rio de Janeiro, Brazil): polyvinyl alcohol 
(PVA), trypan blue powder, dichloromethane (DCM), 
L-tyrosine, monobasic sodium phosphate, dibasic potas-
sium phosphate, and sodium chloride. The following cell 
culture items were purchased from Gibco Invitrogen Cor-
poration (New York, NY): Dulbecco’s modified Eagle’s 
medium (DMEM), glutamine, fetal bovine serum (FBS), 
sodium bicarbonate, sodium hydroxide, Pen Strep (penicil-
lin 10,000 units/mL + streptomycin 10,000 µg/mL aqueous 
solution), and trypsin 1:250 powder. Finally, these items 
were purchased from Sigma-Aldrich (St Louis, MO): 
dimethyl sulfoxide, ethylenediaminetetraacetic acid, N-2-
hydroxyethylpiperazine-N′-2-ethanesulfonic acid, [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] 
(MTT), and PCL.
Nanoparticle preparation
PCL NPs containing L-tyrosine were prepared by the double 
emulsification evaporation method. One hundred milligrams 
of PCL was briefly dissolved in 5 mL of DCM. This organic 
solution was emulsified in 1 mL of 1% PVA with 0.4 mg/mL 
of l-tyrosine aqueous internal phase for 1 min using an 
ultrasonicator (Ultrasonic Processor – UP 100 H, 60 W, 
30 kHz; Hielscher, Germany) in an ice bath. This primary 
emulsion was poured into 20 mL of a 0.5% PVA aqueous 
solution and sonicated again with the same ultrasonic probe 
for 2 min under the same conditions to create the water for 
oil-in-water emulsion. The solvent (DCM) was evaporated 
with stirring at room temperature (28°C). NPs suspensions 
were purified twice by a 30-min centrifugation at 10,000 × g 
(Avanti J-2 cooled ultracentrifuge; Beckman Coulter, San 
Francisco, CA) for 40 min and followed by resuspension in 
4 mL of distilled water.33–35
The suspension was transferred into a glass vial and stored 
at −20°C. Freeze-drying was carried out in a lyophilizer (freeze 
dry system; Labconco, Brazil) and yielded powdered NPs. International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
963
l-Tyrosine-loaded PCL NPs and antitumoral effects of DC
The samples were stored at room temperature (28°C) before 
analysis. The lyophilized samples were resuspended in water 
and observed by optical microscopy to detect the presence 
of aggregates.36
The process yield was calculated using Eq. 1:
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  ×
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T
100   (1)
where Y (%) is the process yield, MNP is the mass of NPs recov-
ered after freeze-drying, and MT is the mass of polymer plus 
the mass of L-tyrosine in formulation before the process. The 
encapsulation method was performed in triplicate (n = 3).
The NPs encapsulation efficiency was determined by 
a spectrophotometric method. The drug was dissolved 
in phosphate-buffered saline (PBS, g/L: 0.26 KH2PO4, 
2.17 Na2HPO4⋅7H2O, 8.71 NaCl), and the absorbance was 
measured at 275 nm (spectrophotometer; UV 2401 PC; 
Shimadzu Kyoto, Japan). The calibration curve was linear 
(r = 0.999) for L-tyrosine in a range of  20–200 µg/mL. Drug 
concentrations were calculated based on the standard curve 
equation. Ten milligrams of freeze-dried NPs was dissolved 
in 5 mL of DCM to dissolve the polymer, and 5 mL of PBS 
was added to preferentially precipitate the polymer. The 
suspension was filtered through a membrane filter (0.22 µm; 
Millex, The Netherlands) to remove the insoluble polymer 
and rediluted with PBS for analysis via the spectrophotomet-
ric method as described above. Encapsulation efficiency was 
calculated from Eq. 2:
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where EE is the encapsulation efficiency, M1 is the mass of 
L-tyrosine (µg) on the NPs, and M2 is the mass of L-PCL (mg). 
The experiments were performed in triplicate (n = 3).
NPs were characterized by size, polydispersity index 
(PI), and electric potential (zeta potential). The size and 
PI of the particles were determined by photon correlation 
spectroscopy using a Zetasizer® 3000 (Malvern Instruments, 
Worcestershire, UK) with a laser reader of 633 nm, operated 
at an angle of 173°, and a temperature of 25°C. The samples 
of L-tyrosine-loaded and unloaded PCL NPs were diluted: 
1:400 (p/v) in distilled water, and 1 mL of this solution was 
added to a plastic cuvette. The zeta potential was measured 
in a 10−3 M NaCl aqueous solution using the electrophoretic 
mode of the device.35 Each sample was measured in triplicate 
for each parameter.
NPs morphology was studied by transmission electron 
microscopy (Morgagni 268; FEI Company, Eindhoven, The 
Netherlands). The sample preparation was performed from 
an aqueous suspension containing 50 mg of NPs in 20 mL of 
distilled water, and 10 µL of this suspension was placed on 
a carbon-coated electron microscopy grid following fixation 
with 10 µL of uranyl acetate 3% (w/v) for 1 min. The grid 
was properly dried and then examined using transmission 
electron microscope.36
The release profile of L-tyrosine-loaded PCL NPs was 
assessed by a dissolution study with spectrophotometric 
analysis.34 A 50-mg sample of NPs loaded with approximately 
1.46 mg of L-tyrosine was resuspended in 10 mL of PBS, 
and this suspension was stirred at 200 rpm and 37°C. At 
time points of 1, 2, 3, 24, 48, 72, and 96 h, the entire content 
was withdrawn and centrifuged at 10,000 rpm for 30 min. 
The supernatant was collected and filtered with a 0.22-µm 
cellulose nitrate membrane; the L-tyrosine concentration was 
determined by spectrophotometry at a wavelength of 275 nm 
(spectrophotometer, UV 2401 PC; Shimadzu). The remaining 
NPs precipitate was resuspended in 10 mL of PBS and 
returned to stirring at 37°C until the next sampling time.
Cell culture
B16F10 cells were obtained from Rio de Janeiro’s Cell 
Bank (UFRJ, Brazil). They were cultured at 37°C in 25-cm2 
culture flasks containing DMEM medium supplemented 
with 10% (v/v) FBS. pH was controlled by the addition of 
3 g/L N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid, 
0.2 g/L NaHCO3, streptomycin (100 µg/mL), and penicillin 
(100 UI/mL) as previously described.28,37 The initial inoculum 
was 5 × 104 cells/mL, which was subcultured every 2 days 
as described elsewhere28,29 and maintained in a log-phase 
growth. Cell detachment was performed with 2 mL of trypsin 
0.05% (w/v) for 2 min.
DC stimulation
After the detachment, B16F10 cells were collected by cen-
trifugation, washed, and suspended (5.0 × 105 cells/mL) 
in PBS (pH 7.4) at 308 mOsm. The cellular suspensions 
were then distributed into a 24-well culture plate (2 mL 
of cell suspension/well). These wells were linked in series 
by filter paper bridges and fitted with platinum electrodes 
at their extremities, which were connected to a DC source 
(FA-3050 model; Instrutherm, Brazil). Control cells were pre-
sented with the same experimental conditions, except for the 
contact with the DC source (Figure 1). Following this approach, 
cell suspensions can be exposed directly to CF, AF, and DC International Journal of Nanomedicine 2010:5
Platinum electrodes
Anodic flow (+) Cathodic flow (−)
Adapted plate lid
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DC source
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Paper bridge Paper bridge
Figure 1 schematic representation of the in vitro system used for DC treatment of B16F10 cells. The cell suspensions are distributed over each individual well and connected to 
a positive pole (AF) and negative pole (CF). An intermediary well, namely electroionic flow (FEI), is connected to the other wells by filter paper bridges moistened with phosphate 
saline buffer. Platinum electrodes are inserted into the AF and CF poles, allowing the system to be connected to a DC source and an amperimeter to monitor DC intensity. 
This distribution permits the separate exposure of cells to cathodic and anodic reactions, and to the DC (FeI). Control cells are exposed to the same conditions, except for the 
use of DC. Internal volume of each well is 0.84 cm3. The distance between the electrodes was 8 cm, and an electric field of approximately 2.5 V/cm was generated.
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without contact with the electrodes, namely electroionic flow 
(EIF) at 25°C. The distance between the electrodes was 8 cm, 
and an electric field of approximately 2.5 V/cm was generated 
as a result. Cell suspensions were treated at room temperature 
with DC of 2 mA, for 0 (control), 2, 4, 6, 8, and 10 min, similar 
to the conditions previously used28–30,38 to assess cell viability. 
In all subsequent experiments, cells were treated for 6 min, an 
intermediate period that was representative of the alterations in 
morphology and viability. The B16F10 cells were preincubated 
for 30 min with different electrolytic suspensions, such as 
PBS, PBS + 181.19 mg of free L-tyrosine, PBS + 0.5 mg/mL 
of unloaded NPs, and PBS + 0.5 mg/L of L-tyrosine-loaded 
PCL NPs, which correspond to approximately 30 µg of 
L-tyrosine. After incubation, DC treatment was performed for 
6 min, the electrolytic media was immediately removed, and 
all of the cells were washed twice with PBS. The cytotoxicity 
of the DC treatment was assessed by the MTT method after 
24 h of incubation with DMEM supplemented with 10% FBS 
as described below.
Cell viability
Cell viability was assessed by measuring the cellular 
mitochondrial activity by the MTT method.39,40 After DC 
treatment, cells were removed from the plate with trypsin 
(as described above) and resuspended in 2 mL of DMEM 
supplemented with FBS 10%; 180 µL of this cellular suspen-
sion was transferred to a 96-well microplate and incubated 
with 20 µL of a 5-mg/L solution of tetrazolium reagent 
(MTT; Sigma-Aldrich) for 3 h at 37°C. The supernatant 
was removed by centrifugation at 1100 rpm for 7 min using 
the CT-6000R Cientec centrifuge (Piracicaba, Brazil). The 
formazan crystals were diluted in 200 µL of pure dimethyl 
sulfoxide (Sigma-Aldrich), and the absorbance was read at 
490 nm on a plate-reading spectrophotometer (thermoplate). 
Viability was calculated as the proportion of absorbance 
of each sample compared to that of the controls (Abssample/
Abscontrol). This experiment was performed in quintuplicate.
Cell growth
To evaluate the influence of DC treatment on B16F10 growth, 
the cells were suspended in 2 mL of PBS (106 cells/mL) 
and treated for 6 min. After DC treatment, the cells were 
washed in PBS, and the suspensions containing similar 
cell numbers were cultivated in a 24-well plate in DMEM 
medium supplemented with FBS 10%. Aliquots of 25 µL 
of the cell suspensions were taken at 0, 24, and 48 h, and International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
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the number of trypan blue-stained and -unstained cells was 
determined in a Neubauer chamber. For the quantitative 
assessment of growth inhibition, trypan blue-stained cells 
were not considered.28,29
Results
Table 1 shows the quantitative analysis of the encapsulation 
process and the characterization parameters of the NPs. The 
double emulsion technique yielded NPs with high homogene-
ity, as detected by the low PIs. PCL-loaded and -unloaded 
NPs showed the same morphological characteristics, as 
could be observed by transmission electron microscope, 
such as an elliptic form and regular borders, with sizes in the 
nanometer range (Figure 2). Indeed, the mean NPs diameters 
measured at the Zetasizer ranged from 244.90 to 269.00 nm 
(Table 1). The unloaded NPs showed significantly lower 
mean diameters when compared to those of the L-tyrosine-
loaded PCL NPs (P , 0.001). However, the size increase 
caused by amino acid insertion did not exceed 10% when 
compared to blank NPs.
The NP surface potential did not show significant altera-
tions after L-tyrosine encapsulation or after AF exposure 
(P . 0.05) (Table 2). The overall process yield was approxi-
mately 50% for both preparations, and the encapsulation 
efficiency reached approximately 30%.
The release kinetics of L-tyrosine from loaded PCL NPs 
is shown in Figure 3. A burst release of approximately 80% 
of the total L-tyrosine was observed within the first 3 h of 
dissolution and subsequently followed by a drastic drop in 
the release rate. After 96 h, the NP content was virtually 
entirely released (data not shown).
Effects of various DC exposure times on B16F10 mela-
noma cell viability are shown in Figure 4A (immediately after 
exposure) and Figure 4B (24 h later). The AF and CF induced 
similar and statistically significant profiles of an immedi-
ate reduction in cell viability after four or more minutes of 
exposure, which was directly proportional to the stimulus 
time (P , 0.01). Twenty-four hours after DC exposure, the 
same viability profile was observed for the AF and CF in 
comparison to untreated control cells. The electroionic flow 
did not induce statistically significant changes in cell viability 
either immediately or 24 h after DC exposure (P . 0.05).
Cell proliferation was assessed 24 and 48 h after a 6-min 
anodic stimulation (Figure 5). The time required to reduce 
the B16F10 cell viability to approximately 60% was 6 min. 
For the cell proliferation experiment, the initial inoculum of 
control and treated cells was 1.33 × 105 and 1.08 × 105 cells, 
respectively. After 48 h, the number of control cells increased 
from 1.33 × 105 to 2.55 × 105. However, after 24 h of treat-
ment, using AF induced a significantly impaired growth of 
B16F10 cells; the number of cells dropped from 1.08 × 105 
to 0.68 × 105, indicating a 54.7% reduction in cell number. 
This inhibition remained in this magnitude for 48 h of 
post-treatment, indicating that B16F10 cells were incapable 
of recovering their proliferation rates.
Effects of AF stimulation in the presence of free and 
encapsulated tyrosine on B16F10 viability are shown in 
Figure 6. This experiment showed that loaded- and unloaded-
PCL NPs did not exhibit any cytotoxic properties. However, 
using AF stimulation in association with tyrosine-loaded 
NPs induced a 40% decrease in cell viability immediately 
(data not shown) and 24 h after treatment, indicating that 
this combination has a promising antineoplastic potential. 
Additionally, the loading process enabled the use of a 
significantly lower amount of tyrosine in its encapsulated 
form when compared to its free form. In fact, the amount of 
tyrosine in the nanosystem was 6000-fold smaller and yet 
induced higher mortality rates (data not shown).
Discussion
Among the morphofunctional features of solid tumors are 
the abnormal function of the lymphatic vasculature, which 
causes fluid retention, and an increased permeability of blood 
vessel walls. Both of these characteristics lead to a higher 
retention of NPs in the tumor area when compared to that 
of normal tissues, resulting in a passive selectivity of the 
system.7 Thus, a small particle size, which is directly related 
to the technique of NPs obtention, is crucial for the desired 
tissue penetration.41
The size of DEEM-yielded NPs depends on many 
factors, such as stirring speed, solution viscosity, organic/
aqueous phase ratio, and PVA concentration in external 
aqueous phase.42 In the present work, the use of sonication in 
conjunction with DEEM produced fine, nanometric-scaled, 
homogeneous pools of loaded- or unloaded-PCL NPs. The 
polydispersity values obtained were approximately 0.1, 
Table 1 Process yield, drug encapsulation efficiency, mean diameter, 
and PI of blank and l-tyrosine-loaded PCL NPs (n = 3 ± sD)
Process 
yield (%)
Encapsulation efficiency 
(μg/100 mg of NP)
Polydispersity 
index
Blank NP 50 ± 1 – 0.075 ± 0.02
l-Tyrosine- 
loaded PCL 
NPs
52 ± 2 30 ± 1.2 0.130 ± 0.02
Notes: Statistically significant difference between blank NP and l-tyrosine-loaded 
PCL NPs. *P , 0.001.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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indicating a monomodal distribution of particle size and a 
very high quality of preparation.43 Furthermore, the loading 
yield is comparable to other findings in the literature4,17 and 
is probably due to the low solubility of L-tyrosine in PBS 
aqueous phase. The surface charge of NPs can be character-
ized by the zeta potential,44 which reflects the electric potential 
Table 2 Zeta potential analyses of blank and l-tyrosine-loaded 
PCL NPs
Before anodic 
flow
After 6 min of  
anodic flow
Blank NP −1.38 ± 0.16 −1.83 ± 0.23
l-Tyrosine-loaded PCL NPs −1.76 ± 0.19 −2.10 ± 0.25
Notes: The experiments were done three times independently (n = 3 ± sD).
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Figure 2 Morphological features and mean diameter of l-tyrosine-loaded PCL NPs. A) Transmission electron micrograph of PCL NPs loaded with l-tyrosine. scale bar: 100 nm. 
B) Diameter distribution of PCL NPs loaded with L-tyrosine determined by photon correlation spectroscopy, showing that most NPs presented diameter in the nanometer 
scale. The experiments were done three times independently (n = 3).
of particles and is influenced by their chemical composition as 
well as the medium in which they are dispersed.2 To assess the 
influence of AF stimulation on the surface charge of the NPs, 
zeta potentials were also measured before and after a 6-min 
AF exposure for both preparations (loaded- and unloaded-
NPs). Indeed, the surface potentials became slightly more 
electronegative after AF, although this increase did not prove 
to be statistically significant in our analysis (P . 0.05).
The majority of the amino acid content was released 
from loaded NPs within the first 3 h at a rate of 80%. 
The release speed depends on the nature of both polymer 
and encapsulated molecule.3 The burst release effect observed 
in our system can be explained by molecules associated pre-
dominantly with the surface and the outer layers of the NP.34 International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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The sustained release is due to the semicrystalline structure 
of PCL NPs and the pores formed in its polymeric matrix 
during the encapsulation process.18 Once in an aqueous 
environment, the PCL NP matrix slowly undergoes ero-
sion, allowing penetration of water into its structure and the 
outward diffusion of L-tyrosine.
This in vitro release study determined that a preincuba-
tion time of 30 min was adequate to ensure the delivery of 
a significant amount of L-tyrosine. In addition, exposure of 
B16F10 cells to a 6-min AF treatment in PBS resulted in an 
immediate cell death of approximately 50% and significant 
impairment of growth recovery after 24 h. These conditions 
have been defined as the most suitable parameters for com-
paring the different experimental groups.
DC is a physical agent capable of destroying different 
kinds of tumor cells, characterizing a tumor therapy (EChT). 
This treatment is noted for its great effectiveness, minimal 
invasiveness, local effect, and low cost.24–26 The principal 
tumor damage induced by DC has been attributed to the 
formation of electrolysis products, which were capable of 
killing the tumor cells.21 Our research group has detected 
the effects of pH acidification and alkalinization induced by 
AF and CF on different tumor cell lines.28–30,38 However, in 
these studies, tumor death was not only attributed exclusively 
to the electrolysis damage, but also to the oxidant species 
generated by the AF.29,30 In fact, the acidification of the AF-
treated medium could not be held responsible for the cell 
killing, as the pH variation induced by anodic reactions is 
not significant (6.5 after 10 min of stimulation).30 Besides, 
when the pH was artificially mimetized by the addition of HCl 
drops, cell viability was not diminished at equivalent rates 
as detected by AF generated by DC source, suggesting the 
role of other electrolysis products, such as reactive chlorine 
and oxygen species, in tumor killing.30
It is common knowledge that DC can both change 
surface cell receptors and also modify cell membrane 
permeability.28,29,45 In fact, this latter property is used 
therapeutically to ease drug penetration into tumor cells, 
a combined technique known as electrochemotherapy.46–48 
In the present study, NPs were produced with PCL; this 
polymer has a negative electrokinetic potential, probably 
due to the presence of some residual functional groups 
with negative charges on the monomer employed in PCL 
polymerization.44 After the loading process and the anodic 
stimulation, we detected a modification of the zeta poten-
tial, but the NPs remained negatively charged. As shown in 
Table 2, these values varied between −1.38 and −2.10 mV. 
Thus, the increase in the cytotoxic effect detected from 
using tyrosine-loaded NPs in conjunction with AF is prob-
ably not due to changes in electrostatic interactions. The 
use of NPs containing amino acids guaranteed a constant 
production and/or delivery of chloramines to tumoral 
cells, which is reflected in increased cellular mortality. In 
fact, using DC in   conjunction with L-tyrosine-loaded PCL 
L
-
t
y
r
o
s
i
n
e
 
r
e
l
e
a
s
e
 
(
%
 
t
o
t
a
l
)
Time (h)
100
80
60
40
20
0
036 9 12 15 18 21 24
Figure 3 release kinetics of l-tyrosine from PCL NPs in a period of 24 h. The experiments were done three times independently (n = 3 ± sD).International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
968
de Campos et al
Control B
Time (min)
V
i
a
b
l
e
 
c
e
l
l
s
 
(
%
) 120,0
100,0
80,0
60,0
40,0
20,0
0,0
2468 10
Anodic flow
Time (min)
V
i
a
b
l
e
 
c
e
l
l
s
 
(
%
) 120,0
100,0
80,0
60,0
40,0
20,0
0,0
2468 10
Cathodic flow
Time (min)
V
i
a
b
l
e
 
c
e
l
l
s
 
(
%
) 100,0
80,0
60,0
40,0
20,0
0,0
246 81 0
Electroionic flow
Time (min)
V
i
a
b
l
e
 
c
e
l
l
s
 
(
%
) 100,0
80,0
60,0
40,0
20,0
0,0
246 81 0
Control
Time (min)
V
i
a
b
l
e
 
c
e
l
l
s
 
(
%
) 125,0
100,0
75,0
50,0
25,0
0,0
2468 10
Anodic flow
Time (min)
V
i
a
b
l
e
 
c
e
l
l
s
 
(
%
) 125,0
100,0
75,0
50,0
25,0
0,0
2468 10
Cathodic flow
Time (min)
V
i
a
b
l
e
 
c
e
l
l
s
 
(
%
) 125,0
100,0
75,0
50,0
25,0
0,0
246 8 10
Electroionic flow
Time (min)
V
i
a
b
l
e
 
c
e
l
l
s
 
(
%
) 125,0
100,0
75,0
50,0
25,0
0,0
246 8 10
A
Figure 4 Kinetics of trypan blue incorporation by both treated and untreated B16F10 cells. A) B16F10 cells were treated with 2 mA of DC for periods varying from 0 to 
10 min and their viability assayed immediately by the trypan blue method. Black squares represent the viability of control cells (■), and the open symbols represent the cells 
treated by the CF (◊), AF (▲), and electroionic flow (□). Anodic and cathodic stimuli induced significant differences in the B16F10 viability when compared to untreated cells 
(P , 0.01), except for the AF stimulus of 2 min. Besides, the electroionic flow stimuli did not induce any changes in cell viability (P . 0.05). B) B16F10 cells were treated for 
periods varying from 0 to 10 min, and their viability was assayed by the trypan blue method 24 h after the treatment. Black squares represent the viability of control cells (■), 
and the open symbols represent the cells treated by the CF (◊), AF (▲), and electroionic flow (□). This graph shows that the cell viability was not recovered, except for the 
cells treated for 4 min with the AF stimulus. As detected immediately after treatment, the electroionic flow stimuli did not induce any changes in cell viability (P . 0.05).
NPs reduced B16F10 viability to approximately 50%; this 
reduction in viability probably resulted from chloramines 
generated within the electrolytic medium, which led to 
cell destruction by apoptosis.31,49,50 Interestingly, the total 
amount of encapsulated amino acid tested was 6000-fold 
lower than that used in the free amino acid experiment 
(data not shown), which justified the use of NPs systems 
to improve the cytotoxicity of DC.
Additionally, necrotic cell death induced by DC is an 
undesirable aspect of this therapy and seems to be directly 
associated to DC intensity, polarity, and time of exposure.30 
This is an important aspect that cannot be neglected in EChT, 
due to the triggering of inflammatory response as well as the 
disarray of tumor structure, which may lead to a systemic spread 
of tumor cells. The constant release of chloramines obtained 
from the interaction of amino groups present in the tyrosine 
and the chlorine species generated by DC is a possible strategy 
to promote cell death by apoptosis rather than necrosis, using 
milder DC intensity/time of exposure regimens. Besides, EChT 
application is most useful in the treatment of solid tumors51 in 
which different electrode   configurations and DC intensities are 
applied. This procedure is not standardized in the literature, yet 
it has presented good results in making inoperable tumors into 
operable ones52,53 and in destroying tumor mass by necrosis.54International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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Figure 5 Treatment of B16F10 cells with DC inhibits cell proliferation. Cells were 
treated with 2 mA of AF for 6 min (▲) and inoculated into fresh media. The number 
of cells treated and untreated (■) was quantified by trypan blue dye after 24 h and 
48 h, considering only the cells that were not permeable to the dye (viable cells). 
The proliferation rate of treated cells was 54.7% lower than the untreated cells. 
Results of five independent experiments expressed as mean ± sD are shown.
D
e
c
r
e
a
s
e
 
i
n
 
c
e
l
l
 
v
i
a
b
i
l
i
t
y
 
(
%
)
Treatments
90
80
70
60
50
40
30
20
10
0
AB CDE
**
*
*
P < 0.01
Figure 6 Decrease in the B16F10 viability induced by different experimental conditions measured by MTT assay. Cells were treated with A) l-tyrosine-loaded PCL NPs, 
B) unloaded NPs, C) 6 min of AF, D) unloaded NPs plus AF, and E) l-tyrosine-loaded PCL NPs plus AF. The percentage of viability decrease was determined immediately 
(data not shown) and 24 h after treatment. The major cell viability decrease (around 60%) was obtained when the l-tyrosine-loaded PCL NPs were associated with AF. 
results of three independent experiments expressed as mean ± sD are shown.
Notes: *Significantly different from control with P , 0.05.
The use of nanotechnology and EChT was first applied 
in C56BL/6Y black mice previously inoculated with 
B16F10 cells with the aim to verify the possibility of trans-
lating the in vitro model to treatment of in situ melanoma. In 
this model, the L-tyrosine-loaded PCL NPs must be injected 
into the solid tumor to avoid NP leakage to normal cells, pro-
tecting these cells from DC damage. The preliminary results 
obtained showed that the association of L-tyrosine-loaded 
PCL NPs with DC induced an almost total destruction of these 
cancer cells after 48 h of treatment, as detected by optical 
and electronic microscopy analyses, with no side effects in 
important organs, such as liver and breast. The safety of this 
treatment for normal cells is probably attributed to the use of 
a biodegradable polymer (PCL) as loader of tyrosine, which 
is a natural amino acid present in living animals, therefore, 
avoiding adverse effects common in traditional anticancer 
treatment. These results are still awaiting confirmation, and 
there are many challenges that need to be faced to permit the 
translatability of in vitro results to in vivo models. Before we 
can consider the use of L-tyrosine-loaded PCL NPs associated 
with DC for in situ cancer treatment, we must face challenges, 
such as the need for a higher number of animals to be studied, 
inoculation of different kinds of tumors, and different elec-
trode configurations and DC intensities among others.
Conclusion
Nanotechnology is generating new perspectives in a number 
of scientific fields. Its applications in cancer medicine are 
currently being investigated with very promising results in 
an in vitro model. The never-before-described use of the 
combination of this technology with EChT aims to make DC 
tumor treatment even more efficient and opens the door for a 
new cancer therapeutic approach. One of the problems associ-
ated with EChT is the occurrence of necrosis, which seems 
to be directly proportional to the DC intensity applied. The 
use of nanotechnology in conjunction with DC may promote 
apoptotic cell death over necrotic damage, especially when 
the AF is applied in the presence of amino acid-loaded NPs. 
In fact, this hypothesis is being tested in C56BL/6Y black 
mice previously inoculated with B16F10 cells, and the results 
obtained so far, however preliminary, are quite successful, 
without any side effects commonly found in traditional 
anticancer treatment, probably due to the use of a biodegrad-
able polymer loaded with a natural amino acid.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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